0547 RLS Patient Odyssey Survey II

Abstract Introduction RLS affects 5%-10% of European and North American adults, with 2%-3% experiencing moderate to severe symptoms. patients, often undiagnosed or improperly treated, experience significant depression in addition loss sleep. Methods ODYSSEY II, an online in-print self-administered questionnaire (respondents primarily from the United States) included validated questions on diagnosis severity, associated medical conditions, treatment responses, access care, standardized PHQ-9 measures. status was confirmed using Cambridge-Hopkins Questionnaire. Analysis linkage scores EQ-5D Health-Related Quality-of-Life (HRQoL) externally methods. Results Of 3,003 mail-in participants, 2,745 were confirmed, 55% having symptoms (IRLS ≥ 21), 86% medications 73% reporting histories dopaminergic augmentation (medication related worsening symptoms).Of RLS-confirmed respondents, average 8.98 for women (US 3.72) 7.22 men 2.67). Among 29% males 40% females (comparable US averages 11% 6.5%) had 10 (moderate, moderately severe) a fourfold risk important (≥ score) depression. Suicidal ideation reported by 15% respondents 4.0%). Associated show that 37% all HRQoL below 50% “full health.”Of six drug classes used treat RLS, three patient-reported efficacy above 60%, but drawbacks, ranging weaker some patients (alpha-2-delta ligands) (dopaminergics, almost three-quarters patients) difficulties obtaining prescriptions (opioids) others.Respondents decade-plus delays time symptom onset diagnosis, still may remain diagnosed inadequately treated. Respondents managed RLSF certified providers better outcomes. Conclusion II documents depression, suicidal thinking losses are very among many patients. report troubling correct diagnosis. Survey results demonstrate best improved when use providers. Improved education both primary care also lead patient Support (If Any) Arbor Pharmaceuticals